The US Food and Drug Administration (FDA) has approved AbbVie's Viekira XR (dasabuvir, ombitasvir, paritaprevir and ritonavir) extended-release tablets, a once-daily, extended-release co-formulation of the active ingredients in Viekira Pak, for patients with chronic genotype-1 (GT1) hepatitis C virus (HCV) infection, including those with compensated cirrhosis.

Viekira XR is a co-formulated three direct-acting antiviral treatment for adult patients with GT1 HCV infection. Its predecessor, Viekira Pak, was first approved by the US FDA in 2014 with or without ribavirin to treat adults with GT1 HCV infection. The product had 2015 global sales of $1.6 billion.

Source: AbbVie